NIH grant conflicts targeted in stimulus amendment

Share this article:
Sen. Herb Kohl
Sen. Herb Kohl
Biomedical researchers receiving grants from the National Institutes of Health would face tougher disclosure rules under an amendment to the economic stimulus bill introduced by Sens. Chuck Grassley (R-IA) and Herb Kohl (D-WI).

The legislation would require NIH to toughen its enforcement of conflict of interest policy and mandate that all grantees receiving funds in excess of $250,000 disclose the amount of the primary investigator's significant financial interest in companies relevant to the research. The grantee institution would have to furnish a detailed report on how it would manage the primary investigator's conflict of interest.

Sen. Grassley, ranking member of the Senate Committee on Finance, said in a statement: “The goal of this initiative is to establish transparency and the accountability that comes from disclosure. It's become clear that the federal rules in place to manage conflicts of interest in research aren't enforced as they ought to be, and there's an opportunity to strengthen them here, as well.”

Kohl, who chairs the Senate Special Committee on Aging, said: “The government has a right to know whether the scientists it funds have a financial stake in the outcome of their research.”

The economic stimulus bill, the senators noted, would add billions to the $24 billion in grants the NIH currently awards each year for biomedical research.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...